Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | DNM2 | P50570 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788121 | 0.98 | ELANE (0.48) | ELANETLR8HCAR3DNM2XDH | |
| SCHEMBL29509040 | 0.95 | TLR8 (0.49) | ELANETLR8HCAR3DNM2XDH | |
| SCHEMBL4113139 | 0.88 | ELANE (0.43) | ELANETLR8HCAR3CNR1 | |
| SCHEMBL8840758 | 0.83 | HRH3 (0.45) | TLR8 | |
| SCHEMBL31119243 | 0.83 | ELANE (0.40) | ELANEXDHGPR84 | |
| SCHEMBL6551974 | 0.82 | NUDT1 (0.43) | GPR84KCNH3 | |
| SCHEMBL3407144 | 0.81 | HRH3 (0.50) | TLR8 | |
| Triphosphate SCHEMBL8435664 | 0.81 | P2RY2 (0.45) | ELANETLR8HCAR3DNM2XDH | |
| Ribose (Furanose) SCHEMBL18152615 | 0.81 | SLC29A1 (0.42) | ELANEGPR84 | |
| Ribose (Furanose) SCHEMBL11356472 | 0.81 | SLC29A1 (0.42) | ELANEGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615767-B | Method for synthesizing 5-fluorocytosine | 新乡拓新药业股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-110615767-A | Method for synthesizing 5-fluorocytosine | 新乡拓新药业股份有限公司 | 2019-12-27 | — | — | CN | claimed |
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4299743-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC Laboratories Co., Ltd. (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230272403-A1 | ANTISENSE OLIGONUCLEOTIDE INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC LABORATORIES CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4201484-A1 | ANTISENSE NUCLEIC ACID INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC Laboratories Co., Ltd. (JP) | 2023-06-28 | — | — | EP | disclosed |
| CN-116199679-A | Industrial preparation method of lamivudine | 吉斯凯(苏州)制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115341005-A | Method for synthesizing cytidine by enzyme method | 深圳华酶生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-3146970-B1 | NUCLEIC ACID DRUG FOR INDUCING SKIPPING OF VARIANT EXON OF CD44 GENE AND INCREASING EXPRESSION OF NORMAL TYPE CD44 MRNA | KNC LABORATORIES CO LTD (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | KNC LABORATORIES CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2012-12-20 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| CN-102234269-A | Industrial preparation method for lamivudine | CHONGQING PHARM RES INST CO | 2011-11-09 | — | — | CN | disclosed |
| WO-2011115513-A2 | A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2011-09-22 | — | — | WO | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| CN-1617726-A | N for the treatment of viral infections4-acylcytosine nucleosides | PHARMASSET LTD (BB) | 2005-05-18 | — | — | CN | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-0411158-B1 | Process for producing nucleosides by using phosphorylases obtainable from Bacillus stearothermophilus | YAMASA SHOYU KK (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | DNMT1, DIMT1, TPMT | ELANE 2971/4885TLR8 2863/4885HCAR3 3937/4885 |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | MYOF, MSTN, MTPN | ELANE 3553/4885TLR8 2177/4885HCAR3 1599/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | ELANE 1081/4885TLR8 525/4885HCAR3 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.